BACKGROUND:Mizoribine (MZR) has been developed as an immunosuppressive agent, but has a less potent immunosuppressive effect up to 3 mg/kg/day MZR. Therefore, we investigated whether high-dose MZR, at 6 mg/kg/day, would be effective and safe for kidney transplant patients in conjunction withcyclosporine (CsA), basiliximab, and corticosteroids. METHODS: A total of 40 living related patients were administeredMZR (6 mg/kg/day), CsA (7 mg/kg/day), prednisolone (maintenance dose 10 mg/day), and basiliximab (20 mg/body). A control group (n = 38) treated with CsA, mycophenolate mofetil (MMF, 25 mg/kg/day), basiliximab, and corticosteroids was also employed in this study. RESULTS: The 2-year graft survival rates for the MZR and MMF groups were 100 and 94.7 %, respectively. The rejection rate in the MZR group (25 %) was not significantly higher than that in the MMF group (16 %). Serum creatinine level was not significant between the two groups. The number of patients who developed cytomegalovirus (CMV) disease was 0 (0 %) in the MZR group and 7 (18.4 %) in the MMF group (P < 0.05). The number of patients treated with ganciclovir was 3 (7.5 %) and 11 (28.9 %) (P < 0.05), respectively. CONCLUSIONS: The combination of high-dose MZR with CsA, basiliximab, and corticosteroids can establish not only satisfactory immunosuppression but also a low rate of CMV infection in vivo.
RCT Entities:
BACKGROUND:Mizoribine (MZR) has been developed as an immunosuppressive agent, but has a less potent immunosuppressive effect up to 3 mg/kg/day MZR. Therefore, we investigated whether high-dose MZR, at 6 mg/kg/day, would be effective and safe for kidney transplant patients in conjunction with cyclosporine (CsA), basiliximab, and corticosteroids. METHODS: A total of 40 living related patients were administered MZR (6 mg/kg/day), CsA (7 mg/kg/day), prednisolone (maintenance dose 10 mg/day), and basiliximab (20 mg/body). A control group (n = 38) treated with CsA, mycophenolate mofetil (MMF, 25 mg/kg/day), basiliximab, and corticosteroids was also employed in this study. RESULTS: The 2-year graft survival rates for the MZR and MMF groups were 100 and 94.7 %, respectively. The rejection rate in the MZR group (25 %) was not significantly higher than that in the MMF group (16 %). Serum creatinine level was not significant between the two groups. The number of patients who developed cytomegalovirus (CMV) disease was 0 (0 %) in the MZR group and 7 (18.4 %) in the MMF group (P < 0.05). The number of patients treated with ganciclovir was 3 (7.5 %) and 11 (28.9 %) (P < 0.05), respectively. CONCLUSIONS: The combination of high-dose MZR with CsA, basiliximab, and corticosteroids can establish not only satisfactory immunosuppression but also a low rate of CMV infection in vivo.
Authors: K Tanabe; T Tokumoto; N Ishikawa; A Kanematsu; T Oshima; M Harano; M Inui; T Yagisawa; I Nakajima; S Fuchinoue; K Takahashi; H Toma Journal: Transplant Proc Date: 1999-11 Impact factor: 1.066
Authors: T Akiyama; H Okazaki; K Takahashi; A Hasegawa; K Tanabe; K Uchida; S Takahara; H Toma Journal: Transplant Proc Date: 2005-03 Impact factor: 1.066
Authors: K Shiraki; M Ishibashi; T Okuno; Y Kokado; S Takahara; K Yamanishi; T Sonoda; M Takahashi Journal: Transplant Proc Date: 1990-08 Impact factor: 1.066
Authors: K Sonda; K Takahashi; K Tanabe; S Funchinoue; Y Hayasaka; H Kawaguchi; S Teraoka; H Toma; K Ota Journal: Transplant Proc Date: 1996-12 Impact factor: 1.066
Authors: T Inou; R Kusaba; I Takahashi; H Sugimoto; K Kuzuhara; Y Yamada; J Yamauchi; O Otsubo Journal: Transplant Proc Date: 1981-03 Impact factor: 1.066
Authors: P Darji; R Vijayaraghavan; C M Thiagarajan; R K Sharma; B Subbarao; R Pishardy; K V Dakshinamurthy; R Vijaykumar; G Abraham; S Bhaskar; L Agarwal; B Shah; A Abraham; M John; K Sampathkumar; T Das; L Umesh; S Sundar; H Ballal; S Jasuja; S Saxena; T K Saha Journal: Transplant Proc Date: 2008-09 Impact factor: 1.066